Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics, Inc. (ARQT) is a leader in developing innovative topical therapies for immune-mediated skin conditions. This page provides investors and medical professionals with essential updates on FDA approvals, clinical trial progress, and strategic initiatives shaping the future of dermatological care.
Access authoritative information about ARQT's non-steroidal treatments for conditions including atopic dermatitis and plaque psoriasis. Our curated news collection features regulatory milestones, research developments, and market analyses to help stakeholders track the company's progress in addressing unmet medical needs.
Key updates include new product launches, clinical trial results, partnership announcements, and scientific presentations. All content is verified through primary sources to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Arcutis' latest advancements in immuno-dermatology. Check regularly for updates on pipeline developments and peer-reviewed research findings that demonstrate the company's commitment to transforming skin disease treatment.
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has announced its participation in three major investor conferences in September 2025.
The company will participate in Citi's 2025 Biopharma Back to School Conference (September 3), Morgan Stanley's 23rd Annual Global Healthcare Conference (September 9), and the HC Wainwright 27th Annual Global Investment Conference (September 10). All presentations will be available via webcast in the "Events" section of Arcutis' website, with replays accessible for 180 days after each conference.
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, has announced the grant of 21,000 restricted stock units to three new employees. The grants were approved by the company's Compensation Committee and issued under the 2022 Inducement Plan.
The stock units, granted on August 1, 2025, will vest over a four-year period, with 25% vesting annually on each anniversary of the vesting commencement date. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Arcutis Biotherapeutics (Nasdaq: ARQT) reported strong Q2 2025 financial results, with net product revenue of $81.5 million, representing a 164% year-over-year increase and 28% sequential growth. The quarter was marked by significant achievements, including FDA approval of ZORYVE foam 0.3% for plaque psoriasis treatment and the initiation of the INTEGUMENT-INFANT study for ZORYVE cream in infants with atopic dermatitis.
Key financial metrics include reduced net loss of $15.9 million ($0.13 per share) compared to $52.3 million in Q2 2024, with cash reserves of $191.1 million. The company's ZORYVE portfolio showed strong performance across all formulations, with over 1 million total prescriptions dispensed to date. Additionally, Arcutis submitted an IND for ARQ-234, a novel fusion protein for atopic dermatitis treatment.
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has scheduled its second quarter 2025 financial results announcement for August 6, 2025 after market close.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Investors can access the live webcast and presentation materials through the "Events" section of Arcutis' website, with an archived replay available afterward on their investor website.
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, has announced the granting of 14,000 restricted stock units to two new employees. The grants were approved by the company's Compensation Committee under the 2022 Inducement Plan, effective July 1, 2025.
The restricted stock units have a four-year vesting schedule, with 25% vesting annually, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced that its product ZORYVE® (roflumilast) cream 0.15% has received a strong recommendation in the American Academy of Dermatology's (AAD) updated guidelines for adult atopic dermatitis management. ZORYVE is the first FDA-approved branded topical PDE4 inhibitor for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis.
Among newly evaluated branded topical therapies, ZORYVE stands out as the only treatment with a strong recommendation for adults with mild to moderate atopic dermatitis. The recommendation highlights the drug's efficacy in improving pruritus and disease severity, favorable tolerability, and low discontinuation rates. The treatment targets a condition affecting over 16 million adults in the United States.
Arcutis Biotherapeutics (NASDAQ: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, June 10, 2025, at 4:00 pm EDT. The event will be accessible via webcast in the "Events" section of Arcutis' website, with the replay remaining available for 180 days after the conference.